Exelixis' Cancer Drug Success Sparks Stock Surge and Positive Analyst Outlook
Exelixis stock rose over 9% after positive results from a study of its next-generation colon cancer drug, zanzalintinib, showing improved survival rates when combined with Roche's Tecentriq, marking a significant milestone in its development program.